Charles River Laboratories International Inc. (NYSE:CRL)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $83.32, but opened at $83.46. Charles River Laboratories International shares last traded at $84.17, with a volume of 100,593 shares traded.

A number of research firms have recently commented on CRL. Credit Suisse Group AG began coverage on Charles River Laboratories International in a report on Monday, June 20th. They issued a “neutral” rating and a $84.00 price objective on the stock. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $92.00 target price on the stock in a report on Friday, June 17th. KeyCorp reiterated a “hold” rating and set a $77.00 target price on shares of Charles River Laboratories International in a report on Sunday, May 22nd. Barclays PLC raised their target price on Charles River Laboratories International from $60.00 to $65.00 and gave the company an “underweight” rating in a report on Friday, May 20th. Finally, Gabelli began coverage on Charles River Laboratories International in a report on Tuesday, April 26th. They set a “buy” rating and a $96.00 target price on the stock. Two research analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. Charles River Laboratories International has an average rating of “Hold” and an average target price of $82.00.

The company has a 50-day moving average of $83.93 and a 200 day moving average of $78.59. The stock has a market capitalization of $4.03 billion and a P/E ratio of 26.31.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, May 4th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.08. The firm earned $354.90 million during the quarter, compared to analysts’ expectations of $354.92 million. During the same quarter last year, the firm earned $0.79 EPS. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. Equities research analysts expect that Charles River Laboratories International Inc. will post $4.39 earnings per share for the current year.

In other news, Director Richard F. Wallman sold 2,720 shares of the company’s stock in a transaction dated Friday, May 6th. The stock was sold at an average price of $81.00, for a total transaction of $220,320.00. Following the completion of the sale, the director now owns 15,430 shares in the company, valued at approximately $1,249,830. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO John J. Crowley sold 1,913 shares of the company’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $85.00, for a total value of $162,605.00. Following the sale, the chief accounting officer now owns 6,883 shares of the company’s stock, valued at approximately $585,055. The disclosure for this sale can be found here.

Several hedge funds recently added to or reduced their stakes in the company. GSA Capital Partners LLP increased its stake in Charles River Laboratories International by 2.1% in the fourth quarter. GSA Capital Partners LLP now owns 59,361 shares of the company’s stock valued at $4,772,000 after buying an additional 1,209 shares during the period. Monarch Partners Asset Management LLC bought a new stake in Charles River Laboratories International during the fourth quarter valued at about $6,978,000. Van Berkom & Associates Inc. increased its stake in Charles River Laboratories International by 5.0% in the fourth quarter. Van Berkom & Associates Inc. now owns 719,334 shares of the company’s stock valued at $57,827,000 after buying an additional 34,470 shares during the period. Vanguard Group Inc. increased its stake in Charles River Laboratories International by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 4,182,744 shares of the company’s stock valued at $336,251,000 after buying an additional 97,314 shares during the period. Finally, Profund Advisors LLC increased its stake in Charles River Laboratories International by 6.6% in the fourth quarter. Profund Advisors LLC now owns 39,295 shares of the company’s stock valued at $3,159,000 after buying an additional 2,445 shares during the period.

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.